Meropenem (Meropenem Anhydrous)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, blocking the final cross‑linking step of peptidoglycan formation. This leads to loss of cell‑wall integrity, osmotic instability and bacterial cell death, providing a bactericidal effect against many Gram‑negative and Gram‑positive organisms.

The dosage of Meropenem is individualized by the prescribing clinician based on the type and severity of infection, patient weight, renal function and local susceptibility patterns. Dosing regimens are established in clinical guidelines and should be followed as directed by a qualified healthcare professional.

Safety data for Meropenem during pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss the risk‑benefit profile with the patient and consider alternative therapies when appropriate.

To order Meropenem, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and the necessary import documentation.

Meropenem belongs to the carbapenem class, offering broader Gram‑negative coverage and greater stability against many β‑lactamases compared with earlier carbapenems such as imipenem‑cilastatin. It also has a lower risk of nephrotoxicity than some combination regimens, making it a preferred option for multidrug‑resistant infections when susceptibility data support its use.

Meropenem for injection should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Once reconstituted, the solution should be used within the time frame specified in the product labeling and kept under the same temperature conditions until administration.

Meropenem is supplied as a sterile powder for injection. It is reconstituted with a compatible diluent and administered intravenously, usually as a short infusion over 15‑30 minutes. The exact infusion rate and duration are determined by the prescriber based on the infection type and patient condition.

The most serious adverse events include seizures, especially in patients with renal impairment or pre‑existing CNS disorders, severe hypersensitivity reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Prompt recognition and medical intervention are essential if any of these events occur.

Meropenem is contraindicated in individuals with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is also advised for patients with severe renal impairment who have not had dose adjustments, and for those with a history of seizures unless benefits clearly outweigh the risks.